Tag: National Institute of Allergy and Infectious Diseases (NIAID)

Handful of Peanuts

Peanut Allergy More Common in Adults Than Children, Many Report First...

Peanut allergy affects at least 4.5 million adults in the US.
Rosie with Auto-Injectors

Epinephrine Not Being Used Often Enough for Anaphylaxis in Children

Nearly a quarter of kids presenting at emergency department with anaphylaxis in study received
COVID-19 Vaccine

NIH Rushing to Find Cause of Rare Allergic Reactions to COVID-19...

"This is not a simple study design. We expect to be looking at highly allergic individuals. They will be not necessarily so easy to recruit, either."
Baby

FARE Launches SEED to Study and Promote Early Introduction of Allergenic...

Study will investigate whether feeding multiple allergenic foods to infants can reduce their risk for developing food allergies.
NanoVax Platform

BlueWillow Completes Preclinical Studies of Intranasal Peanut Allergy Vaccine

Preclinical studies of a peanut vaccine have been completed while the company has begun preclinical studies of a milk allergy vaccine and is ready to begin studies of an egg allergy vaccine.
Sesame Seeds

NIH Researchers Estimate 17% of Food-Allergic Children Have Sesame Allergy

“Given how frequently sesame allergy occurs among children who are allergic to other foods, it is important to use caution to the extent possible when exposing these children to sesame.”
BlueWillow Biologics

BlueWillow Awarded NIH Contract to Advance Development of its Therapeutic Peanut...

Research Will Progress Treatment for Millions Suffering from Peanut Allergies.
Peanuts

Study: Few People with Peanut Allergy Tolerate Peanut after Stopping OIT

Continuing with a modest dose confers more protection, NIH-funded study finds.
T-Cell

Scientists Discover Immune Cell Subtype in Mice That Drives Allergic Reactions

NIH-funded study suggests targeting cell may help prevent anaphylaxis in humans.
Omalizumab + OIT

Clinical Trial to Evaluate Experimental Treatment in People Allergic to Multiple...

NIH and partners to assess whether Omalizumab can reduce allergic reactions.